Fiera Capital Corp Raises Stock Holdings in Insmed, Inc. $INSM

Fiera Capital Corp grew its position in shares of Insmed, Inc. (NASDAQ:INSM) by 29.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 748,037 shares of the biopharmaceutical company’s stock after acquiring an additional 168,800 shares during the quarter. Fiera Capital Corp owned about 0.39% of Insmed worth $75,282,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey lifted its position in Insmed by 83.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 67,903 shares of the biopharmaceutical company’s stock valued at $6,834,000 after purchasing an additional 30,803 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Insmed by 8.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 11,576 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 933 shares in the last quarter. S&CO Inc. purchased a new stake in shares of Insmed during the 2nd quarter valued at about $835,000. Vise Technologies Inc. bought a new position in shares of Insmed in the 2nd quarter valued at about $584,000. Finally, Pier 88 Investment Partners LLC purchased a new position in Insmed in the second quarter worth about $652,000.

Insider Buying and Selling

In related news, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the transaction, the director owned 262,675 shares of the company’s stock, valued at $38,190,318.25. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Roger Adsett sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the transaction, the chief operating officer owned 105,637 shares in the company, valued at $13,477,168.46. The trade was a 19.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 179,787 shares of company stock worth $26,428,149 over the last 90 days. Corporate insiders own 3.00% of the company’s stock.

Insmed Price Performance

INSM opened at $194.39 on Thursday. The business has a fifty day moving average of $160.42 and a 200 day moving average of $118.99. The stock has a market cap of $41.46 billion, a P/E ratio of -34.04 and a beta of 1.05. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $197.08.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same quarter last year, the business posted ($1.27) earnings per share. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on INSM. UBS Group upped their price objective on Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Guggenheim increased their price target on Insmed from $125.00 to $172.00 and gave the company a “buy” rating in a report on Monday, September 8th. Wells Fargo & Company raised their price target on Insmed from $171.00 to $217.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Jefferies Financial Group boosted their price objective on shares of Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Finally, Mizuho set a $196.00 target price on shares of Insmed in a research note on Wednesday, October 29th. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $173.29.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.